Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Zarnestra

ZARNESTRA 100 bid (phase II recommended dose defined in phase I)will be administered continuously from one week prior to start of radiation therapy until the last day of radiation therapy.

PROCEDURE

standard Radiation therapy

Radiotherapy will be focused on the initial tumour volume with a reasonable margin of safety (2 cm). A total dose of 60 Gray (Gy) will be given to the Clinical Target Volume

Trial Locations (2)

Unknown

Centre Jean Perrin, Clermont-Ferrand

Institut Claudius Regaud, Toulouse

All Listed Sponsors
collaborator

Janssen-Cilag Ltd.

INDUSTRY

lead

Institut Claudius Regaud

OTHER

NCT00209989 - Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter